KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY Trial.

Vlado Perkovic, Jonathan Barratt, Richard Lafayette, Adrian Liew, Yusuke Suzuki, Kevin Carroll, Chee Kay Cheung, Vladimír Tesař, Hernán Trimarchi, Muh Geot Wong, Hong Zhang, Jing Xia, Cecile Fajardo, Lokesh Shah, Jeffrey Hafkin, Dana V Rizk

Kidney Int Rep 10(12) 4207-4218

PMID41426046
PMCIDPMC12712463
DOI10.1016/j.ekir.2025.09.031
发表日期2025-12-22
摘要

摘要

INTRODUCTION: IgA nephropathy is the most common primary glomerulonephritis and a leading cause of kidney failure worldwide. Treatments that target the underlying immune drivers of the disease to improve long-term patient outcomes are needed. Sibeprenlimab, a selective A Proliferation-Inducing Ligand (APRIL) inhibitor that significantly decreases pathogenic galactose-deficient IgA1 (Gd-IgA1) production and immune complex formation, is being investigated in the ongoing phase 3 VISIONARY trial. Here, we summarize the overall study design and report on the baseline characteristics of patients enrolled in the trial. METHODS: VISIONARY is a multicenter, double-blind, placebo-controlled trial (ClinicalTrials.gov identifier, NCT05248646; study date of registration: 2022-02-18). Adults with biopsy-confirmed IgA nephropathy were randomized 1:1 to receive subcutaneous (s.c.) sibeprenlimab 400 mg or placebo once every 4 weeks for 26 doses. The primary end point is the 24-hour urine protein-to-creatinine ratio (uPCR-24 h) at 9 months compared with the baseline. RESULTS: Of 510 enrolled patients across 31 countries, 58.8% were male, 59.0% were Asian, and 57.3% lived in East or South/Southeast Asia. The median age was 42.0 (range, 18.0-83.0) years; 97.8% of patients were using renin-angiotensin system inhibitors (RASis), and 45.1% were using sodium-glucose cotransporter 2 inhibitors. The mean (SD) baseline uPCR-24 h was 1.54 (0.92) g/g. The mean (SD) baseline urine protein was 2.1 (1.3) g/d, and the mean (SD) baseline estimated glomerular filtration rate (eGFR) was 64.2 (25.3) ml/min per 1.73 m2. CONCLUSION: VISIONARY, the largest IgA nephropathy trial to date, is evaluating the efficacy and safety of s.c. sibeprenlimab in a broadly representative population with IgA nephropathy at high risk of disease progression.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。